The combination of CDK4/6 and PI3K inhibitors resulted in the regression of breast cancer grafts with PIK3CA mutations, and the combination of PI3K, AKT, and mTORC1/2 inhibitors demonstrated increased efficacy in multiple preclinical models of breast cancer. Here, AKT1 is linked to breast carcinoma.